Watson Pharmaceuticals, a specialty pharmaceutical company, has received FDA approval of an oral contraceptive product, a low dose oral contraceptive to combine 0.8mg norethindrone and 0.025mg ethinyl estradiol in chewable form, with four 75mg ferrous fumarate, or iron, placebo tablets.
134739
Watson Pharmaceuticals receives FDA approval for oral contraceptive product
36029
BPA shows tangible effects on health endpoints at high dosage levels
173138
Milestone Scientific acquires additional patent rights for painless injections
52550
Corcept Therapeutics submits NDA for the use of Corlux in Cushing's Syndrome
48863
Birth control pills can continue to be sold over the counter
83928
FDA approves Egrifta for treatment of lipodystrophy in people with HIV
19743
Boston Scientific assigned patent for drug delivery
4472
Watson Pharmaceuticals to voluntarily recall drug
69339
New birth control pills can cause blood clot
9895
New compounds kill ovarian, testicular, head and neck cancer cells with less toxicity
50758
FDA approves first prostate cancer vaccine
62799
Asthma pills work, goodbye inhalers!
132441
Pulmatrix launches iSPERSE, a novel inhaled dry powder drug delivery platform
124569
BioAlliance Pharma announces the
1515
Combination of anastrozole and fulvestrant extends survival in women with metastatic breast cancer
140704
Amgen licenses molecule for the treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc.
123993
FDA approves new drug for multiple sclerosis